Journal article
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
- Abstract:
-
BACKGROUND: In patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL), a short duration of response to therapy or adverse cytogenetic abnormalities are associated with a poor outcome. We evaluated the efficacy of ibrutinib, a covalent inhibitor of Bruton's tyrosine kinase, in patients at risk for a poor outcome. METHODS: In this multicenter, open-label, phase 3 study, we randomly assigned 391 patients with relapsed or refractory CLL or SLL to receive daily ibrutinib...
Expand abstract
- Publication status:
- Published
Actions
Authors
Bibliographic Details
- Publisher:
- Massachussetts Medical Society
- Journal:
- New England journal of medicine
- Volume:
- 371
- Issue:
- 3
- Pages:
- 213-223
- Publication date:
- 2014-07-01
- DOI:
- EISSN:
-
1533-4406
- ISSN:
-
0028-4793
- Source identifiers:
-
477988
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:477988
- UUID:
-
uuid:94ed6162-805c-4b48-8ada-f98fabde922f
- Local pid:
- pubs:477988
- Deposit date:
- 2014-09-21
Terms of use
- Copyright date:
- 2014
If you are the owner of this record, you can report an update to it here: Report update to this record